EUVIMEDExplore EUVIMED
CrossrefInfo card

Immune Checkpoint Inhibitor‐Induced Diabetic Ketoacidosis in a Patient With Pre‐Existing Type 2 Diabetes: A Case Report

Lingfen Zeng, Jieming Sun

Clinical Case Reports · 2026-11 · 14 (11)

DOI: 10.1002/ccr3.73834 ↗
AbstractBibliographic details

Abstract

ABSTRACT Immune checkpoint inhibitors (ICIs) may cause rare life‐threatening ICI‐associated diabetes mellitus. We report a 60‐year‐old Chinese male with pre‐existing type 2 diabetes who developed toripalimab‐induced diabetic ketoacidosis after 3 treatment cycles. He also had toripalimab‐related hyperthyroidism. Clinicians should closely monitor plasma glucose during and after ICI therapy.

Knowledge that fits your work.

From a free start through personal literature research to the complete Research Suite.

View plans →

Are all publisher full texts included?

No. Bibliographic records, abstracts and full texts are different content types. Full-text availability depends on the source, open access and your existing licences. An EUVIMED plan does not replace additional publisher rights.

View plans →